Segment Reporting

The Company has three operating segments, Pharmacy Services, Retail/LTC and Health Care Benefits, as well as a Corporate/Other segment. The Company’s segments maintain separate financial information, and the CODM evaluates the segments’ operating results on a regular basis in deciding how to allocate resources among the segments and in assessing segment performance. The CODM evaluates the performance of the Company’s segments based on adjusted operating income. Effective for the first quarter of 2019, adjusted operating income is defined as operating income (GAAP measure) excluding the impact of amortization of intangible assets and other items, if any, that neither relate to the ordinary course of the Company's business nor reflect the Company's underlying business performance. Segment financial information for the three months ended March 31, 2018 has been retrospectively adjusted to conform with the current period presentation. See the reconciliation of consolidated operating income (GAAP measure) to adjusted operating income below for further context regarding the items excluded from operating income in determining adjusted operating income. The Company uses adjusted operating income as its principal measure of segment performance as it enhances the Company’s ability to compare past financial performance with current performance and analyze underlying business performance and trends. Non-GAAP financial measures the Company discloses, such as consolidated adjusted operating income, should not be considered a substitute for, or superior to, financial measures determined or calculated in accordance with GAAP.

Effective for the first quarter of 2019, the Company realigned the composition of its segments to correspond with changes to its operating model and reflect how the CODM reviews information and manages the business. See Note 1 ‘‘Significant Accounting Policies’’ for further discussion. Segment financial information for the three months ended March 31, 2018, has been retrospectively adjusted to reflect these changes as shown below:




	Three Months Ended March 31, 2018
	Pharmacy			Retail/		Health Care			Corporate/			Intersegment			Consolidated
In millions	Services			LTC		Benefits			Other			Eliminations			Totals
Revenues, as previously reported	$	32,220		$	20,432	$	—		$	48		$	(6,957	)	$	45,743
Adjustments	326			—		1,318			—			(1,644		)	—
Revenues, as adjusted	$	32,546		$	20,432	$	1,318		$	48		$	(8,601	)	$	45,743

Cost of products sold ⁽¹⁾	$	29,751		$	14,516	$	—		$	—		$	(6,762	)	$	37,505
Adjustments	1,556			—		—			—			(1,556		)	—
Cost of products sold	$	31,307		$	14,516	$	—		$	—		(8,318		)	$	37,505

Benefit costs ⁽¹⁾	$	1,329		$	—	$	—		$	—		$	—		$	1,329
Adjustments	(1,329		)	—		1,329			—			—			—
Benefit costs	$	—		$	—	$	1,329		$	—		$	—		$	1,329

Operating expenses, as previously reported	$	377		$	4,292	$	—		$	264		$	(20	)	$	4,913
Adjustments	(39		)	—		127			—			(88		)	—
Operating expenses, as adjusted	$	338		$	4,292	$	127		$	264		$	(108	)	$	4,913

Operating income (loss), as previously reported	$	763		$	1,624	$	—		$	(216	)	$	(175	)	$	1,996
Adjustments	138			—		(138		)	—			—			—
Operating income (loss), as adjusted	901			1,624		(138		)	(216		)	(175		)	1,996
Adjustments	86			212		1			(2		)	—			297
Adjusted operating income (loss)	$	987		$	1,836	$	(137	)	$	(218	)	$	(175	)	$	2,293

^{_____________________________________________}


(1)	The total of cost of products sold and benefit costs were previously reported as cost of revenues.

The following is a reconciliation of financial measures of the Company’s segments to the consolidated totals:




	Pharmacy		Retail/		Health Care			Corporate/			Intersegment			Consolidated
In millions	Services⁽¹⁾		LTC		Benefits			Other			Eliminations⁽²⁾			Totals
Three Months Ended
March 31, 2019
Revenues from customers	$	33,558	$	21,115	$	17,706		$	25		$	(11,007	)	$	61,397
Net investment income	—		—		164			85			—			249
Total revenues	33,558		21,115		17,870			110			(11,007		)	61,646
Adjusted operating income (loss)	947		1,489		1,562			(231		)	(172		)	3,595
March 31, 2018
Revenues from customers	$	32,546	$	20,432	$	1,316		$	—		$	(8,601	)	$	45,693
Net investment income	—		—		2			48			—			50
Total revenues	32,546		20,432		1,318			48			(8,601		)	45,743
Adjusted operating income (loss)	987		1,836		(137		)	(218		)	(175		)	2,293

^{_____________________________________________}


(1)	Revenues of the Pharmacy Services segment include approximately $3.3 billion of retail co-payments for each of the three-month periods ended March 31, 2019 and 2018.

(2)

Intersegment eliminations relate to intersegment revenue generating activities that occur between the Pharmacy Services segment and the Retail/LTC segment for the three months ended March 31, 2018. Effective November 28, 2018, intersegment eliminations also relate to intersegment revenue generating activities that occur between the Health Care Benefits segment and the Pharmacy Services segment and/or the Retail/LTC segment.

The following is a reconciliation of consolidated operating income to adjusted operating income for the three months ended March 31, 2019 and 2018:




	Three Months Ended
	March 31,
In millions	2019		2018
Operating income (GAAP measure)	$	2,690	$	1,996
Amortization of intangible assets ⁽¹⁾	622		210
Acquisition-related transaction and integration costs ⁽²⁾	148		43
Store rationalization charge ⁽³⁾	135		—
Loss on divestiture of subsidiary ⁽⁴⁾	—		86
Interest income on financing for the Aetna Acquisition ⁽⁵⁾	—		(42		)
Adjusted operating income	$	3,595	$	2,293

^{_____________________________________________}

(1)

Intangible assets relate to the Company's acquisition activities and are amortized over their useful lives. The amortization of intangible assets is reflected in the Company's unaudited GAAP condensed consolidated statements of operations in operating expenses within each segment. The amortization of intangible assets is not directly related to the core performance of the Company's business operations.

(2)

During the three months ended March 31, 2019, acquisition-related integration costs relate to the Aetna Acquisition. During the three months ended March 31, 2018, acquisition-related transaction and integration costs relate to the acquisitions of Aetna and Omnicare, Inc. The acquisition-related transaction and integration costs are reflected in the Company’s unaudited GAAP condensed consolidated statements of operations in operating expenses primarily within the Corporate/Other segment.

(3)

During the three months ended March 31, 2019, the store rationalization charge primarily relates to operating lease right-of-use asset impairment charges in connection with the planned closure of 46 underperforming retail pharmacy stores in the second quarter of 2019. The store rationalization charge is reflected in the Company’s unaudited GAAP condensed consolidated statements of operations in operating expenses within the Retail/LTC segment.


(4)	During the three months ended March 31, 2018, the loss on divestiture of subsidiary represents the pre-tax loss on the sale of the Company’s RxCrossroads subsidiary for $725 million and is reflected in operating expenses in the Company’s unaudited GAAP condensed consolidated statement of operations within the Retail/LTC segment.


(5)	During the three months ended March 31, 2018, the Company recorded interest income of $42 million on the proceeds of its unsecured senior notes issued in March 2018 to partially fund the Aetna Acquisition. All amounts are for the periods prior to the close of the Aetna Acquisition, which occurred on November 28, 2018, and were recorded within the Corporate/Other segment.